Bioforce Nanosciences Holdings (BFNH) Change in Accured Expenses (2019 - 2026)

Bioforce Nanosciences Holdings (BFNH) has 8 years of Change in Accured Expenses data on file, last reported at $101250.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 710.52% year-over-year to $101250.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $510559.0 (up 19.29% YoY) and the FY2025 annual result came in at $421801.0, changed 0.28% from the prior year.
• Change in Accured Expenses declined to $101250.0 in Q1 2026, from $419928.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $422323.0 in Q4 2023 to a low of -$210823.0 in Q3 2023.
• A 5-year average of $80184.5 and a median of $101250.0 in 2026 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 94791.26% in 2023, down 47582.66% in 2023.
• Tracing BFNH's Change in Accured Expenses over 5 years: stood at -$446.0 in 2022, then soared by 94791.26% to $422323.0 in 2023, then sank by 74.96% to $105750.0 in 2024, then surged by 297.1% to $419928.0 in 2025, then plunged by 75.89% to $101250.0 in 2026.
• The last three Change in Accured Expenses figures came in at $101250.0 (Q1 2026), $419928.0 (Q4 2025), and -$209627.0 (Q3 2025), per Business Quant data.